AstraZeneca is working with multiple countries and organizations to make the early-stage coronavirus vaccine widely accessible around the world. The company acknowledged that the vaccine might work, but pledged to put its resources behind the effort. They received more than $1 billion from the US Biomedical Advanced Research and Development Authority for the development, production and delivery of the vaccine starting in the fall. With that grant, AstraZeneca secured its first agreement for 400 million doses of the vaccine in trial. If the vaccine is successful, the United States would get 300 million doses, according to Reuters.